Please login to the form below

Not currently logged in
Email:
Password:

MRC Technology appoints director of technology transfer

Andrew Farquharson will join the firm from September 1

MRC Technology has named Andrew Farquharson as director of technology transfer, effective from September 1.

Farquharson will lead the team responsible for identifying, protecting and progressing promising life science research to improve human health.

Commenting on his appointment, Farquharson said: “I am greatly looking forward to joining the MRCT team and using my experience to meet the challenges in ensuring that future innovations are protected and translated into meaningful new therapeutic products made available to patients.”

Farquharson has previously held senior intellectual property (IP) roles at AstraZeneca UK and USA, supporting the firm's R&D, business development and government affairs activities.

He currently runs a consultancy practice, which provides IP services to a breadth of life science and pharma clients. 

Farquharson is additionally appointed to the EU Commission's Expert Group, advising on the European Biotech Directive's impact on patent law and R&D activities.

Dr Dave Tapolczay, CEO at MRC Technology, added: “Andrew's extensive experience will support our charity's work to ensure innovative life science research reaches its full potential and benefit a wider range of people. We look forward to having him on board.”

8th July 2015

From: Research

Share

Tags

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Havas Life Medicom

We’re a specialist-led, unified communications agency delivering connected healthcare communications, informed through fresh insights, smart thinking and inspired ideas. Our...

Latest intelligence

Mistrust in medical research: a patient perspective
The recent development of several COVID-19 vaccines has placed medical research firmly in the spotlight, highlighting public confusion and misinformation about clinical trials. Patient advocate, Trishna Bharadia reveals what the...
Real-world evidence: breaking boundaries in rare disease
Generating data for drug launches is a challenging process. In rare diseases, with small patient populations and high unmet need, evidence generation is even more complex. Consultant Sarah Poole and...
The heavy toll of COVID-19 on cancer patients
We all know that finding and treating cancer early saves lives. During the COVID-19 pandemic, oncology treatments paused while cancer continued to spread. So, what has been the impact of...

Infographics